Desperate for good news
17 April 2020

Drugmaker Gilead’s anecdotal success treating Covid-19 sent its stock and the broader market up. It’s not total fantasy – even small changes in the odds of society reopening ought to boost asset prices. The gain in Gilead’s own stock is harder to explain.